SCHEMBL22717309

SCHEMBL22717309

COC(=O)c1ccc(Br)nc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
MAPT P10636 2/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
ABL1 P00519 1/20 0.45
KDM4E B2RXH2 4/20 0.43
LMNA P02545 1/20 0.43
TSHR P16473 1/20 0.43
TUBB4A P04350 1/20 0.41
TUBB P07437 1/20 0.41
TUBA3C P0DPH7 1/20 0.41
TUBA1B P68363 1/20 0.41
TUBA4A P68366 1/20 0.41
TUBB4B P68371 1/20 0.41
TUBB3 Q13509 1/20 0.41
TUBB2A Q13885 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL391203 0.82 POLB (0.50) SMN1; SMN2L3MBTL1NPC1RAB9AMAPT
SCHEMBL22658874 0.81 L3MBTL1 (0.45) SMN1; SMN2L3MBTL1NPC1RAB9AMAPT
SCHEMBL424747 0.81 TUBB4A (0.54) SMN1; SMN2L3MBTL1NPC1RAB9AMAPT
SCHEMBL29450481 0.81 TUBB4A (0.54) SMN1; SMN2L3MBTL1NPC1RAB9AMAPT
SCHEMBL29587479 0.81 L3MBTL1 (0.45) SMN1; SMN2L3MBTL1NPC1RAB9AMAPT
SCHEMBL13072040 0.81 TSHR (0.49) SMN1; SMN2KDM4ETSHRCA12CA1
SCHEMBL24818230 0.80 LMNA (0.48) SMN1; SMN2L3MBTL1NPC1RAB9AMAPT
SCHEMBL14686821 0.80 NPC1 (0.54) SMN1; SMN2L3MBTL1NPC1RAB9AMAPT
SCHEMBL334079 0.80 EGFR (0.50) SMN1; SMN2L3MBTL1NPC1RAB9AMAPT
SCHEMBL1615811 0.80 NPC1 (0.46) SMN1; SMN2L3MBTL1NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049074-A1 THIADIAZOLYL DERIVATIVES IDEAYA BIOSCIENCES, INC. (US) 2026-02-19 US disclosed
US-12509454-B2 Thiadiazolyl derivatives IDEAYA BIOSCIENCES, INC. (US) 2025-12-30 US disclosed
EP-3976608-B1 THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES INC (US) 2023-11-08 EP disclosed
EP-3976608-B1 THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES INC (US) 2023-11-08 EP disclosed
US-20230078112-A1 THIADIAZOLYL DERIVATIVES IDEAYA BIOSCIENCES, INC. 2023-03-16 US disclosed
EP-3976608-A1 THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS Ideaya Biosciences, Inc. (US) 2022-04-06 EP disclosed
CN-114127062-A Thiadiazolyl derivatives as inhibitors of DNA polymerase Theta 伊迪亚生物科学有限公司 2022-03-01 CN disclosed
WO-2020243459-A1 THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2020-12-03 WO disclosed
CN-106170489-B New Pyrazolopyrimidine derivative and its purposes as MALT1 inhibitor 诺华股份有限公司 2019-05-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049074-A1 THIADIAZOLYL DERIVATIVES POLH, POLM, POLD1 SMN1; SMN2 4185/4885L3MBTL1 1234/4885NPC1 2942/4885
US-20230078112-A1 THIADIAZOLYL DERIVATIVES POLQ, POLK, POLA1 SMN1; SMN2 3104/4885L3MBTL1 2727/4885NPC1 3141/4885
US-12509454-B2 Thiadiazolyl derivatives POLD1, POLQ, DNA2 SMN1; SMN2 1964/4885L3MBTL1 3784/4885NPC1 3834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.